Literature DB >> 29889662

Progress in achieving long-term HIV remission.

Maria Pino1, Mirko Paiardini1,2, Vincent C Marconi1,2,3,4.   

Abstract

PURPOSE OF REVIEW: The purpose of the present review is to describe the major barriers to HIV eradication and assess the most promising cure strategies under investigation. RECENT
FINDINGS: There are significant challenges to achieve HIV eradication. These include the establishment of persistent latently infected cells, systemic chronic immune activation, and immune dysfunction. Since the announcement of the first HIV cure involving the Berlin patient, several attempts to reproduce these results have failed. Thus, it is widely accepted that long-term HIV remission would be a more feasible approach. Optimization of ART, immune-based therapies, therapeutic vaccinations, and gene editing, amongst others, are strategies aimed at controlling HIV in the absence of ART. These new strategies alone or in combination are being developed in preclinical studies and clinical trials and will provide further insight into whether long-term HIV remission is possible.
SUMMARY: The present review discusses several mechanisms that mediate the persistence of the HIV reservoir, clinical cases that provide hope in finding a functional cure of HIV, and promising interventional strategies being tested in preclinical studies and clinical trials that attempt to reduce the HIV reservoirs and/or boost the immune responses to control HIV in the absence of ART.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29889662      PMCID: PMC8696266          DOI: 10.1097/COH.0000000000000487

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  91 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 2.  HIV therapeutic vaccines: moving towards a functional cure.

Authors:  Geetha H Mylvaganam; Guido Silvestri; Rama Rao Amara
Journal:  Curr Opin Immunol       Date:  2015-05-18       Impact factor: 7.486

3.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

Review 4.  HIV-1 Reservoirs During Suppressive Therapy.

Authors:  Kirston Barton; Anni Winckelmann; Sarah Palmer
Journal:  Trends Microbiol       Date:  2016-02-12       Impact factor: 17.079

5.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Authors:  Julian H Elliott; James H McMahon; Christina C Chang; Sulggi A Lee; Wendy Hartogensis; Namandje Bumpus; Rada Savic; Janine Roney; Rebecca Hoh; Ajantha Solomon; Michael Piatak; Robert J Gorelick; Jeff Lifson; Peter Bacchetti; Steven G Deeks; Sharon R Lewin
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

6.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

7.  Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).

Authors:  Jean-Michel Molina; Yves Levy; Isabelle Fournier; Stephanie Hamonic; Michèle Bentata; Genevieve Beck-Wirth; Marie-Lise Gougeon; Alain Venet; Isabelle Madelaine; Daniel Sereni; François Jeanblanc; Thomas Boulet; François Simon; Jean-Pierre Aboulker
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

8.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

Review 9.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  4 in total

1.  Epidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018.

Authors:  Tingting Yue; Pan Zhang; Yuantao Hao; Jianmei He; Jun Zheng; Erik De Clercq; Guangdi Li; Yaxiong Huang; Fang Zheng
Journal:  Front Public Health       Date:  2022-06-09

2.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 3.  Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV.

Authors:  Christina Gavegnano; Andrea Savarino; Taofeek Owanikoko; Vincent C Marconi
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

4.  Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.

Authors:  Adam Gilbertson; Joseph D Tucker; Karine Dubé; Maartje Dijkstra; Stuart Rennie
Journal:  BMC Med Ethics       Date:  2021-12-28       Impact factor: 2.652

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.